Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(21 sites)
United States
University of Michigan ( Site 6000), Ann Arbor, Michigan DUHS Duke Blood Cancer Center ( Site 6005), Durham, North Carolina The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus, Ohio UPMC Hillman Cancer Center ( Site 6004), Pittsburgh, Pennsylvania Australia
Royal Prince Alfred Hospital ( Site 1003), Camperdown, New South Wales Royal North Shore Hospital ( Site 1001), St Leonards, New South Wales Sunshine Coast Hematology and Oncology Clinic ( Site 1006), Buderim, Queensland Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002), Southport, Queensland Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000), Adelaide, South Australia Monash Health ( Site 1004), Clayton, Victoria Hong Kong
Queen Mary Hospital ( Site 1601), Hksar Italy
Azienda Ospedaliera Universitaria Careggi ( Site 2700), Florence, Tuscany Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703), Alessandria IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702), Bologna Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701), Varese New Zealand
North Shore Hospital-Department of Haematology ( Site 1401), Auckland Aotearoa Clinical Trials ( Site 1400), Auckland United Kingdom
Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402), London, Hammersmith and Fulham Boston Pilgrim Hospital ( Site 3403), Boston, Lincolnshire University College London Hospital ( Site 3400), London, London, City of Guy's & St Thomas' NHS Foundation Trust ( Site 3401), London, London, City of